Precision Oncology & Genetic Testing: The New Era of Cancer Treatment in India.

When I first started practicing oncology, cancer treatment largely followed a one-size-fits-all approach. Today, the landscape has changed dramatically. We’ve entered an era where genetic and molecular insights allow us to choose therapies tailored to each patient’s tumor biology. This is precision oncology India — an approach that’s reshaping how we treat and think about cancer.

Understanding precision oncology

Precision oncology isn’t about doing more tests—it’s about doing the right tests for the right patient. Tumors are driven by genetic mutations, and identifying these through genetic testing cancer India helps us find actionable targets. For example, detecting an EGFR mutation in lung cancer or a BRCA alteration in breast cancer can directly influence therapy choices. Instead of relying only on chemotherapy, we can offer targeted treatments that are often more effective and better tolerated.

Why it matters for India in India

precision oncology poses both promise and challenge. The promise lies in better outcomes and fewer side effects. The challenge is access and cost. While next-generation sequencing (NGS) has become more affordable, many patients still hesitate due to expense or lack of awareness. Encouragingly, several Indian labs now offer molecular oncology India panels at a fraction of international prices, and hospitals are integrating tumor boards to interpret results meaningfully. The focus should not be just on testing—but on using the information intelligently.

Beyond mutations: the bigger picture

Precision oncology goes beyond identifying a mutation and prescribing a pill. It involves understanding resistance mechanisms, tumor heterogeneity, and the evolving genetic landscape as treatment progresses. Liquid biopsies are emerging as less invasive tools for serial monitoring—allowing us to adapt therapy in real time. As Indian oncologists, we must balance innovation with pragmatism: using molecular tools when they clearly guide clinical benefit, and avoiding them when they add cost without changing management.

Building infrastructure and expertise

To make precision oncology routine, we need not just machines but people—molecular pathologists, data scientists, and clinicians who can interpret genomic data responsibly. Collaborative initiatives between hospitals, academia, and start-ups are already building this ecosystem. The next step is integrating these results into national cancer registries so that data from Indian patients can shape global research.

The take-home message

Precision oncology is not science fiction anymore—it’s everyday practice. For patients, the key question is not “Can I get this test?” but “Will this test help guide my treatment?” When used judiciously, genetic testing cancer India can transform outcomes, reduce trial-and-error therapy, and save lives. As oncologists, our role is to ensure these technologies serve patients, not profit motives. Molecular oncology India is here to stay—but its success depends on thoughtful application, ethical transparency, and equitable access.

By Dr. Amol Akhade, Medical Oncologist, Fortis Hospital Mumbai – specializing in precision oncology, clinical research, and digital education in cancer care.